Novo Nordisk’s Teen Pill Win Offers a Rebound, But the Payer Puzzle Remains Unsolved

Novo Nordisk closed the week with a 6.4% bounce to €35.09, its best single-day showing in months, after unveiling positive Phase 3a data from the PIONEER TEENS trial. The study marks the first clinical evaluation of an oral GLP-1 therapy in adolescents aged 10 to 17 with type 2 diabetes—a population that has long been underserved by drugmakers. The primary endpoint was hit with a statistically significant 0.83 percentage-point reduction in HbA1c versus placebo at 26 weeks. Novo plans to file for regulatory expansion of Rybelsus in both the US and EU during the second half of the year.

The clinical win was a welcome relief for a stock that has shed more than 21% since January and now trades at roughly 10.8 times earnings—a steep discount to the pharmaceutical sector average of 16x and the peer group’s 19x. The shares remain well below their 200-day moving average of €42.79, and the year-to-date loss underscores just how much headroom the company needs to reclaim.

Yet beneath the headline rebound, the week delivered a series of conflicting signals that paint a far more complicated picture for investors. The most immediate headwind came from Washington, where the Centers for Medicare & Medicaid Services’ BALANCE pilot program—designed to pave the way for Medicare coverage of weight-loss drugs like Wegovy—hit a wall. Major insurers UnitedHealth and CVS Health have both declined to participate, with CVS publicly exiting the model and UnitedHealth citing “significant challenges and open questions” about the program’s structure. The news hit Novo’s shares hard on Tuesday, wiping out more than 4%, while Eli Lilly lost roughly 3.8%. CMS has extended the pilot’s timeline through the end of 2027 with government funding, but the insurer pullback raises serious doubts about near-term uptake.

The BALANCE model, which targets more than 50 million older Americans, locks in manufacturer prices at $245 per month and caps patient out-of-pocket costs at $50. Without major payer participation, the program risks becoming a hollow framework rather than the commercial catalyst Novo needs. The company’s full-year 2026 guidance already calls for a 5% to 13% revenue decline at constant exchange rates, and the BALANCE stutter only adds to the pressure ahead of its first-quarter earnings report due in May.

On the competitive front, the week brought clearer evidence that Novo’s oral semaglutide is gaining ground against Eli Lilly’s Foundayo. An indirect comparison of the OASIS 4 and ATTAIN-1 studies showed oral semaglutide 25 mg delivering roughly three percentage points more weight loss than Lilly’s orforglipron 36 mg over 64 weeks—13.6% versus 11.2%. Patients on orforglipron discontinued treatment due to gastrointestinal side effects at about 14 times the rate of those on semaglutide, and 84% of survey respondents preferred the oral semaglutide profile. One caveat: the FDA approved Foundayo at a lower dose than the one used in the comparison study, so the head-to-head data is not perfectly transferable.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The real-world numbers tell a similar story. Foundayo recorded just 3,707 prescriptions in its second week on the market, compared to 18,410 for Novo’s oral Wegovy version over the same period—nearly a fivefold gap. Analysts have slashed their 2026 revenue forecasts for Foundayo from as high as $5 billion to a range of $1.3 billion to $1.5 billion. Lilly’s stock fell nearly 5% on Friday to €750, and the company will face tough questions about prescription dynamics when it reports first-quarter results on April 30.

Novo’s buyback program, meanwhile, continues to chug along quietly. Since February, the company has repurchased roughly 12.3 million B-shares for about 3.1 billion Danish kroner, as part of a total program worth 15 billion kroner. The first tranche runs through early May, offering a modest floor for the stock even as broader headwinds persist.

The pipeline calendar remains dense. The Ozempic pill—oral semaglutide for type 2 diabetes, already marketed as Rybelsus in Europe—is expected to launch in the US during the second quarter of 2026. The ongoing legal challenge to the IRA’s Medicare price negotiations continues, with semaglutide selected for 2025 talks and the new price set to take effect in 2027. Wegovy prescriptions rose 7% week-over-week, a signal of commercial momentum that Novo will need to sustain.

For Novo Nordisk, the PIONEER TEENS data offers a genuine clinical differentiator and a potential growth lever in an underserved pediatric market. But the stock’s valuation discount, the Medicare coverage vacuum, and the looming revenue decline suggest that one good trial result—however impressive—cannot alone reverse the gravity of the challenges ahead. The next few weeks, with Lilly’s earnings on April 30 and Novo’s own report in May, will test whether the rebound has legs or is merely a temporary reprieve.